Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.68 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 6/20 | 0.96 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.96 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.96 |
| ▸ | MEN1 | O00255 | 3/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.96 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.96 |
| ▸ | MAPT | P10636 | 2/20 | 0.96 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | TSHR | P16473 | 2/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | SHBG | P04278 | 4/20 | 0.68 |
| ▸ | PGR | P06401 | 3/20 | 0.68 |
| ▸ | AR | P10275 | 3/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.68 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL27624098 | 1.00 | LMNA (0.96) | LMNANR3C1HIF1AMEN1KMT2A | |
| SCHEMBL22761988 | 0.98 | LMNA (1.00) | LMNANR3C1HIF1AMEN1KMT2A | |
| SCHEMBL4877448 | 0.98 | LMNA (1.00) | LMNANR3C1HIF1AMEN1KMT2A | |
| SCHEMBL37494 | 0.98 | LMNA (1.00) | LMNANR3C1HIF1AMEN1KMT2A | |
| SCHEMBL13069287 | 0.98 | LMNA (1.00) | LMNANR3C1HIF1AMEN1KMT2A | |
| SCHEMBL27035399 | 0.98 | LMNA (1.00) | LMNANR3C1HIF1AMEN1KMT2A | |
| SCHEMBL15445000 | 0.98 | LMNA (1.00) | LMNANR3C1HIF1AMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL28349042 | 0.97 | LMNA (0.98) | LMNANR3C1HIF1AMEN1KMT2A | |
| Cyclopropane Carboxylic Acid SCHEMBL27035116 | 0.94 | LMNA (0.88) | LMNANR3C1HIF1AMEN1KMT2A | |
| Formic Acid SCHEMBL28467407 | 0.94 | LMNA (0.92) | LMNANR3C1HIF1AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 915 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3041509-B1 | NKR3 ANTAGONISTS FOR TREATING OR PREVENTING HOT FLUSHES | IMPERIAL COLLEGE INNOVATIONS LTD (GB) | 2023-07-12 | — | — | EP | claimed |
| WO-2022257986-A1 | USE OF CYP450 INHIBITOR IN INHIBITING OR KILLING MITES AND TREATING DRY EYE SYNDROME | 广州岐微生物医药科技有限公司 | 2022-12-15 | — | — | WO | claimed |
| CN-110139692-A | For adjusting the heteroaryl amines and its preparation method and purposes of hedgehog approach | 财团法人生物技术开发中心 | 2019-08-16 | — | — | CN | claimed |
| CN-108254481-A | A kind of method of multi-class drug and personal care articles and pesticide in quick detection water | 深圳先进技术研究院 | 2018-07-06 | — | — | CN | claimed |
| CN-107106531-A | The enhanced chemoimmunotherapy of chemical induction immunotherapy method haptens in minimally invasive accurate individuation knubble | 于保法 | 2017-08-29 | — | — | CN | claimed |
| CN-105934246-A | Tetrahydroquinoline compositions as BET bromodomain inhibitors | 福马疗法公司 | 2016-09-07 | — | — | CN | claimed |
| EP-3041509-A1 | METHOD FOR TREATING OR PREVENTING HOT FLUSHES | Imperial Innovations Limited (GB) | 2016-07-13 | — | — | EP | claimed |
| WO-2015033163-A1 | METHOD FOR TREATING OR PREVENTING HOT FLUSHES | IMPERIAL INNOVATIONS LIMITED (GB) | 2015-03-12 | — | — | WO | claimed |
| CN-101171034-B | Humanized L243 antibodies | IMMUNOMEDICS INC | 2014-06-18 | — | — | CN | claimed |
| CN-103687624-A | Targeted polymeric conjugates and uses thereof | UNIV RAMOT | 2014-03-26 | — | — | CN | claimed |
| US-20040033267-A1 | Nanoparticulate compositions of angiogenesis inhibitors | ELAN PHARMA INTERNATIONAL LTD. | 2004-02-19 | — | — | US | claimed |
| WO-2003080027-A1 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS | ELAN PHARMA INTERNATIONAL, LTD. (IE) | 2003-10-02 | — | — | WO | claimed |
| CN-1429104-A | Inhibitors of 17 beta-hydroxysteroid dehydrogenase type 5 and 3 and methods of use thereof | ENDORECH INC (CA) | 2003-07-09 | — | — | CN | claimed |
| CN-1106839-C | Controlled release of steroids from sugar coattings | HYETH INC (US) | 2003-04-30 | — | — | CN | claimed |
| US-6531139-B1 | Self-emulsifying formulation which provide high concentration and high oral bioavailability for lipophilic, pharmaceutically active agents | PHARMACIA & UPJOHN COMPANY | 2003-03-11 | — | — | US | claimed |
| US-20030044434-A1 | Self-emulsifying formulation for lipophilic compounds | GAO PING (US) | 2003-03-06 | — | — | US | claimed |
| EP-0999826-A1 | SELF-EMULSIFYING FORMULATION FOR LIPOPHILIC COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 2000-05-17 | — | — | EP | claimed |
| CN-1244806-A | Compositions for transdermal administration of steroid drugs | LG CHEMICAL LTD (KR) | 2000-02-16 | — | — | CN | claimed |
| WO-1999006024-A1 | SELF-EMULSIFYING FORMULATION FOR LIPOPHILIC COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 1999-02-11 | — | — | WO | claimed |
| CN-1141168-A | Controlled release of steroids from sugar coattings | AMERICAN HOME PROD (US) | 1997-01-29 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030044434-A1 | Self-emulsifying formulation for lipophilic compounds | MGLL, LIPA, LIPC | ESR1 4038/4885ESR2 3788/4885LMNA 1218/4885 |
| US-20040033267-A1 | Nanoparticulate compositions of angiogenesis inhibitors | VEGFA, KDR, FLT1 | ESR1 3791/4885ESR2 3194/4885LMNA 3968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.